Ampersand Biosciences, a Boston, MA-based multi-product platform company developing smart medicines, raised $65M in Series B Funding.
Backers included Ampersand’s founder, Flagship Pioneering, Eli Lilly & Company, and several additional new investors.
The company intends to use the funds to drive the acceleration of its initial pipeline of programs, including one in immuno-inflammation and another in immuno-oncology, both of which are planned to enter IND-enabling studies in 2025.
Led by CEO Jason Gardner, Ampersand Biomedicines enables a new way of programming medicines that work precisely where needed in the body and nowhere else. Its computationally empowered Address, Navigate, Determine (AND)™ platform identifies ideal addresses for drug localization and informs the design of AND-Body™ Therapeutics that have the optimal therapeutic effect.
AND-Body Therapeutics are designed to localize to their intended target and conditionally actuate biology to treat disease, enabling improved target engagement while limiting on-target, off-tissue side effects.
FinSMEs
19/03/2025